OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
56
Results
Show all
Save search
Copy query
Show results for
Unknown
(56)
Publication Date
Release Date
2021
(12)
2025
(10)
2022
(9)
2023
(7)
2024
(5)
2018
(3)
2017
(3)
2013
(2)
2026
(1)
2020
(1)
2019
(1)
2015
(1)
2014
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
Optimizing Nutritional Care with Machine Learning: Identifying Sarcopenia Risk Through Body Composition Parameters in Cancer Patients-Insights from the NUTritional and Sarcopenia RIsk SCREENing Project (NUTRISCREEN).
Not available
S-EPMC12030622
|
biostudies-literature
Cite
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Not available
S-EPMC5956072
|
biostudies-literature
Cite
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study.
Not available
S-EPMC8918146
|
biostudies-literature
Cite
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Not available
S-EPMC8423885
|
biostudies-literature
Cite
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
Not available
S-EPMC9422942
|
biostudies-literature
Cite
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.
Not available
S-EPMC5293737
|
biostudies-literature
Cite
Polyelectrolyte complexes based on a novel and sustainable hemicellulose-rich lignosulphonate for drug delivery applications.
Not available
S-EPMC11499397
|
biostudies-literature
Cite
First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
Not available
S-EPMC12357791
|
biostudies-literature
Cite
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.
Not available
S-EPMC6095177
|
biostudies-literature
Cite
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Not available
S-EPMC3832513
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets